Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 4/20 | 0.55 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.55 |
| ▸ | MASP2 | O00187 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | BRS3 | P32247 | 1/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27992257 | 0.89 | SCN2A (0.55) | NPY5RSCN2AMASP2RAB9ABRS3 | |
| SCHEMBL11229277 | 0.85 | SCN2A (0.52) | NPY5RSCN2AMASP2RAB9ABRS3 | |
| SCHEMBL30852800 | 0.85 | SCN9A (0.59) | NPY5RSCN2AMASP2RAB9ABRS3 | |
| SCHEMBL15135617 | 0.84 | NPY5R (0.50) | NPY5RSCN2AMASP2RAB9APIN1 | |
| SCHEMBL29213500 | 0.84 | KDM4E (0.53) | BRS3PIN1NQO2MAPTKDM4E | |
| SCHEMBL31301442 | 0.84 | SCN2A (0.54) | NPY5RSCN2ARAB9APDE10AMAPT | |
| SCHEMBL24208563 | 0.80 | SCN2A (0.57) | NPY5RSCN2ASCN9A | |
| SCHEMBL2026067 | 0.80 | MAPT (0.56) | NPY5RSCN2AMASP2RAB9AMAPT | |
| SCHEMBL27491435 | 0.78 | PIN1 (0.51) | NPY5RPIN1SCN9A | |
| SCHEMBL30518801 | 0.77 | HPGDS (0.34) | NPY5RBRS3PIN1HPGDSSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844020-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | Exelixis, Inc. (US) | 2007-10-17 | — | — | EP | claimed |
| WO-2007024744-A2 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | EXELIXIS, INC. (US) | 2007-03-01 | — | — | WO | claimed |
| WO-2006076202-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTORS LIGANDS | EXELIXIS, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| US-20220204476-A1 | RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-06-30 | — | — | US | disclosed |
| WO-2022133588-A1 | RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-06-30 | — | — | WO | disclosed |
| EP-3263583-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | Pharmascience Inc. (CA) | 2018-01-03 | — | — | EP | disclosed |
| EP-1844020-B1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | EXELIXIS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-2534170-B1 | IAP BIR DOMAIN BINDING COMPOUNDS | PHARMASCIENCE INC (CA) | 2017-04-19 | — | — | EP | disclosed |
| EP-2534170-B1 | IAP BIR DOMAIN BINDING COMPOUNDS | PHARMASCIENCE INC (CA) | 2017-04-19 | — | — | EP | disclosed |
| CN-102985439-B9 | IAP BIR domain binding compounds | 制药科学股份有限公司 | 2016-08-03 | — | — | CN | disclosed |
| CN-102985439-B | IAP BIR domain binding compounds | 制药科学股份有限公司 | 2016-06-15 | — | — | CN | disclosed |
| US-20130040892-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | PHARMASCIENCE INC. (CA) | 2013-02-14 | — | — | US | disclosed |
| US-20130040892-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | PHARMASCIENCE INC. (CA) | 2013-02-14 | — | — | US | disclosed |
| EP-2534170-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | Pharmascience Inc. (CA) | 2012-12-19 | — | — | EP | disclosed |
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2011098904-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011098904-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2011-08-18 | — | — | WO | disclosed |
| EP-1844020-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | Exelixis, Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007024744-A2 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | EXELIXIS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2006076202-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTORS LIGANDS | EXELIXIS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204476-A1 | RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF | SARS1, NSUN3, GTF3C4 | NPY5R 3924/4885SCN2A 4387/4885MASP2 807/4885 |
| US-20130040892-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | NPY5R 4784/4885SCN2A 3535/4885MASP2 829/4885 |
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1B, IL1A, IL1R1 | NPY5R 3583/4885SCN2A 2403/4885MASP2 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.